Eczema Free Forever™ Eczema Free Forever™

Neurotoxin pipeline advances, stay wary of counterfeits

As the neurotoxin market is set for expansion, so, too, expands the market of counterfeit products. One expert reviews the innovative options coming up through the pipeline and cautions colleagues about the risks associated with counterfeit products.. Learn more
Modern medicine – Dermatology Times

Aarkstore Enterprise – Atopic Dermatitis – Pipeline Assessment and Market Forecasts to 2017

Aarkstore announce a new report  “Atopic Dermatitis – Pipeline Assessment and Market Forecasts to 2017 ” through its vast collection of market research report.

Summary

“Atopic Dermatitis – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Atopic Dermatitis therapeutics market. The report identifies the key trends shaping and driving the global Atopic Dermatitis therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Atopic Dermatitis sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated the global atopic dermatitis therapeutics market to be valued at $ 728m in 2009. It is expected to grow to $ 942m at a Compound Annual Growth Rate (CAGR) of 3.3% by 2017. This growth is primarily attributed to an increase in competition among existing products and the presence of a strong pipeline with more emerging therapies. Globally, the US remains the largest market for atopic dermatitis therapeutics, and was valued at $ 415m in 2009.However, with most of the demand expected to come from the developed economies, the center of global atopic dermatitis therapeutics market activity is potentially due for a paradigm shift.

Scope

The scope of the report includes:
– Annualized global Atopic Dermatitis therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
– Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
– Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Anti-inflammatory, Corticosteroid, Interleukin Inhibitor, Antimicrobial, Immunomodulators, Protease Inhibitor, Nuclear Factor-Kappa B (NF-kB) inhibitor, Selective cannabinoid 2 receptor agonist, T-cell inhibitor, Vitamin D derivative, Cytokine Modulator, NO synthase inhibitor, Kinase Inhibitor,Calcineurin Inhibitor, Anti-pruritic, Histamine H1 antagonist, Chymase inhibitor, Anti-Neoplastic, TNF Antagonist, Non-steroid, Anti-itching, Vaccine, Combination, H4R antagonist, Serine proteinase inhibitor, RAFT modulator, Neurokinin 1 (NK1) receptor agonists, Vascular adhesion protein-1 (VAP-1) inhibitor, non-comedogenic, Fibroblast Growth Factor (FGF) inhibitor, TSLP interaction Inhibitor, Phosphodiesterase 4 (PDE4) Inhibitor, NGF receptor blocker and Glucocorticoid receptor agonist.
– Analysis of the current and future market competition in the global Atopic Dermatitis therapeutics market. The key future market players covered are Provectus Pharmaceuticals, AnGes MG Inc., Creabilis Therapeutics, Asubio Pharma, Almirall, Anacor Pharma, MIKA Pharma GmbH, Shionogi USA, Inc. and Serentis Ltd
– Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
– Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the Atopic Dermatitis market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
– Develop business strategies by understanding the trends shaping and driving the global Atopic Dermatitis therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global Atopic Dermatitis therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
– What’s the next big thing in the global Atopic Dermatitis therapeutics market landscape? Identify, understand and capitalize.

For more information, please visit:
http://www.aarkstore.com/reports/Atopic-Dermatitis-Pipeline-Assessment-and-Market-Forecasts-to-2017-65421.html
Or email us at press@aarkstore.com or call +919272852585

Aarkstore Enterprise specialize in providing online market business information on market research reports, books, magazines, conference booking at competitive prices, and strive to provide excellent and innovative service to our customers. We are built on the premise that reading is valuable, capable of stirring emotions and firing the imagination. Whether your looking for new product trends or competitive analysis of a new or existing market, Aarkstore Enterprise has the best resource.

Find More Atopic Dermatitis Articles

Atopic Dermatitis – Pipeline Assessment And Market Forecasts To 2017

GlobalData estimated the global atopic dermatitis therapeutics market to be valued at $ 728m in 2009. It is expected to grow to $ 942m at a Compound Annual Growth Rate (CAGR) of 3.3% by 2017. This growth is primarily attributed to an increase in competition among existing products and the presence of a strong pipeline with more emerging therapies. Globally, the US remains the largest market for atopic dermatitis therapeutics, and was valued at $ 415m in 2009. However, with most of the demand expected to come from developed economies, the center of global atopic dermatitis therapeutics market activity is potentially due for a paradigm shift.
For further details, please click or add the below link to your browser:

http://www.globaldata.com/reportstore/Report.aspx?ID=Atopic-Dermatitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

In 2009, there were approximately 35 million cases of atopic dermatitis reported within the seven geographies (the US, the UK, Germany, France, Spain, Italy and Japan). This equated to a prevalence of approximately 5%. GlobalData estimates that the number of atopic dermatitis patients is forecast to increase to about 42 million by 2017, representing an increase in prevalence. Some of the factors associated with an increased risk of atopic dermatitis include small family size, higher socioeconomic and educational levels regardless of ethnicity, movement from a rural to an urban environment, and an increased use of antibiotics. Research has indicated that there is a predominance of type-2 helper T cells (Th2) in atopic dermatitis. A higher number of cases would involve the increased uptake of therapeutics, thereby increasing the growth of the market.

The global atopic dermatitis market is heavily fragmented, with numerous generic products at relatively low prices. The patent expiry of marketed products such as Protopic and Elidel in the period 2012 2015 would allow the further entry of generic products at cheaper prices, reducing market growth as well as the market size.

GlobalData, the industry analysis specialist, has released its new report, Atopic Dermatitis – Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Atopic Dermatitis therapeutics market. The report identifies the key trends shaping and driving the global Atopic Dermatitis therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global Atopic Dermatitis sector.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Atopic-Dermatitis-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.globaldata.com

For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries

Related Atopic Dermatitis Articles